Aeluma, Inc. Form 8-K Summary
Business Context and Reporting Period
The filing reports the June 22, 2021 reverse merger of former shell company Parc Investments, Inc. with Biond Photonics, Inc. Biond became the accounting acquirer and wholly owned operating subsidiary, and the registrant changed its name to Aeluma, Inc. The filing was signed June 28, 2021 and includes historical financial information for the years ended December 31, 2020 and 2019 and the quarter ended March 31, 2021.
Aeluma develops optoelectronic devices using compound semiconductor materials integrated on large-diameter silicon wafers, targeting photodetectors, imaging, lidar, augmented reality, facial recognition and communications applications. The company remained in the research and development stage with no commercial products or revenue.
Key Financial Metrics and Capitalization
- Revenue was $0 for the three months ended March 31, 2021 and 2020, and for the years ended December 31, 2020 and 2019.
- Net loss was $14,463 for the quarter ended March 31, 2021, versus $48 for the comparable 2020 quarter.
- Net loss was approximately $13,469 for 2020 versus $249 for 2019. The filing also references $13,502 in one discussion, creating an internal inconsistency.
- First-quarter 2021 operating expenses were $12,963, including $11,663 of professional fees and $1,300 of general and administrative expenses. Interest expense was $1,500.
- Cash was $158,454 at March 31, 2021, compared with $38,302 at December 31, 2020. Total assets were $358,663 and total liabilities were $366,643 at March 31, 2021.
- Working capital was $1,811 at March 31, 2021, compared with a deficit of $109,607 at December 31, 2020.
- Net cash used in operations was $81,594 for the quarter ended March 31, 2021 and $1,377 for 2020. Net cash used in investing activities was $3,456 for the quarter and $106,228 for 2020.
- Financing activities generated $205,202 in the first quarter of 2021 and $145,701 in 2020, primarily from SAFE financing, equity issuance and notes payable.
- The company raised gross proceeds of $7.77 million through a private placement of 3,885,000 shares at $2.00 per share. Placement agent commissions were $715,900, with approximately $35,000 of expenses reimbursed; estimated total offering fees and expenses were approximately $1.0 million.
- Following the merger and offering, up to 10,535,000 common shares were outstanding, with 348,500 placement-agent warrants outstanding and 980,000 shares reserved under the 2021 Equity Incentive Plan.
- The filing does not provide a clear post-offering cash balance, debt balance or margin measure.
Material Changes Versus Prior Period and Corporate Changes
- Professional fees increased from $0 to $11,663 in the first quarter of 2021, while general and administrative expenses increased from $48 to $1,300.
- Interest expense increased from $0 to $1,500 in the first quarter of 2021, primarily from related-party loans.
- The company completed a change-of-control transaction and ceased to be a shell company.
- Former directors Ian Jacobs and Mark Tompkins resigned. Jonathan Klamkin became President and Chief Executive Officer, and Lee McCarthy became interim Chief Financial Officer and Chief Operating Officer. Steven DenBaars joined the board.
- The company dismissed Raich Ende Malter & Co. LLP and engaged Rose, Snyder & Jacobs LLP as its independent registered public accounting firm. The filing reports no disagreements with the former auditor.
- The company adopted amended and restated governing documents, a classified three-class board structure and the 2021 Equity Incentive Plan.
Outlook, Liquidity, Risks and Unusual Items
Management expects to install and qualify its MOCVD equipment, conduct development runs, pursue initial wafer purchase agreements with two potential customers, develop photodetector products and engage foundries for engineering samples and future production. The two customer support letters are non-binding, and the company had no customers or sales contracts at the filing date.
The financial statements raise substantial doubt about the company’s ability to continue as a going concern. Management states that existing cash resources are insufficient to complete its business plan and that additional debt or equity financing will be required. The company expects continuing losses and negative operating cash flows until it achieves commercial revenue, if ever.
- Material risks include the absence of revenue, an unproven business model, limited operating history, dependence on additional financing, potential dilution, and reliance on key personnel and third-party suppliers.
- The company had material weaknesses in internal control over financial reporting related to insufficient accounting and SEC reporting personnel and expertise.
- The common stock was not listed or quoted on any exchange or OTC market. The company intended to seek OTCQB quotation but could not assure that quotation or an active trading market would develop.
- All outstanding shares were restricted securities at the filing date. Registration rights covered merger shares, offering shares, placement-agent shares and 2.5 million pre-merger shares.
- Registration delays could trigger monetary penalties generally calculated at 12% per annum, subject to specified conditions and an 8% maximum of affected share value.
- Approximately 4.1 million merger shares were subject to lock-up restrictions extending 18 months after the first qualifying trading date.
- COVID-19, semiconductor supply constraints, export controls, environmental requirements, intellectual-property challenges, customer qualification delays and manufacturing scale-up were identified as additional risks.
Investor Verification Checklist
- Verify the final audited financial statements, going-concern qualification, debt obligations and post-offering cash balance in the filed exhibits.
- Reconcile the inconsistent references to the 2020 net loss and offering expense estimates.
- Confirm the final closing date and exact number of shares sold in the private placement; the filing contains conflicting references to an additional June 28 closing amount.
- Review the merger agreement, registration rights agreement, lock-up agreements and placement-agent warrants for dilution, resale and penalty provisions.
- Track whether the resale registration statement was filed and declared effective within the stated deadlines and whether the stock obtained OTC quotation.
- Assess progress toward MOCVD installation, customer qualification, commercial contracts and revenue generation.
- Monitor remediation of the identified material weaknesses and the company’s need for additional financing.